The pharmaceutical industry is at a pivotal moment. Artificial intelligence (AI) is shifting from improving processes to reshaping disease treatment and care delivery.
Jörg Möller's sojourn as chief executive of BenevolentAI has come to an abrupt end after just nine months, as the company names co-founder Ken Mulvany as its executive chairman.
Flagship Pioneering-backed artificial intelligence start-up Generate:Biomedicines has attracted another big pharma partnership, this time with Novartis.